Establishing Development, Manufacturing and Sales Structures and Securing Partners
First written in FY2023. 1 of 2 entries say "Mitigated", first in FY2024-Q3. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3MitigatedAnnual report
「JIXING has strong development capabilities and could be an optimal partner. Although development milestones would decrease from $165 million to $12.5 million, the transaction was evaluated on the assumption that the Company would acquire the Japanese rights to TMS-007 and the new JX09 program and develop and commercialize them itself.」
The transfer from Biogen to JIXING HK and the partnership with JIXING and RTW secured a new development and capital partner for TMS-007. - FY2023First statedAnnual report
「If the Company cannot secure or maintain appropriate partners, if the terms of agreements with partners are not optimal, or if a partner has difficulty developing the product, establishing manufacturing methods, building manufacturing capacity or establishing a sales structure for any reason, the Company’s results and future business development could be materially affected.」
The Company highlights the possibility that it may be unable to secure or maintain appropriate partners or that partners may be unable to establish development, manufacturing and sales structures.